| Followers | 138 |
| Posts | 9252 |
| Boards Moderated | 0 |
| Alias Born | 04/28/2011 |
Tuesday, July 08, 2025 11:48:48 AM
Movement! Nice to see.
Recent CCCC News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 11:17:23 AM
- C4 Therapeutics shares jump on expanded oncology collaboration with Roche • IH Market News • 04/09/2026 02:57:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 11:07:35 AM
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) • GlobeNewswire Inc. • 04/09/2026 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:44 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:20:02 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 12:49:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:09:49 PM
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- C4 Therapeutics to Participate in Upcoming March Conferences • GlobeNewswire Inc. • 02/23/2026 12:10:00 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 02/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:04:38 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 06:45:15 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/09/2026 09:01:00 PM
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 • GlobeNewswire Inc. • 02/04/2026 12:00:00 PM
